전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved31 programs
CGTLimited DatastalePorteus, Matthew, MDPreclinical

Allogeneic Stem Cell Transplant (Allogeneic Stem Cell Transplant)

Hematologic Diseases · Hematologic Diseases

#HematologicDiseases#CGT#Preclinical#Popular#cell-gene-therapy+4
Trials 91Status Recruiting
CGTStandard DatabasestaleBristol-Myers SquibbPhase 2

Metoprolol (Metoprolol)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 85Status Active
AntibodyCurated CorestaleEpizyme, Inc.Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 49Status Recruiting
CGTLimited DatastaleArtiva Biotherapeutics, Inc.Phase 1

NK cells/Combined Monoclonal Antibodies (NK cells/Combined Monoclonal Antibodies)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 48Status Recruiting
AntibodyLimited DatastaleEpizyme, Inc.Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#RelapsedHematologicMalignancy+3
Trials 48Status Discontinued
CGTLimited DatastaleKecellitics Biotech Company LtdPreclinical

anti-CD19 CAR (anti-CD19 CAR)

Pediatric Cancers; Hematologic Malignancies · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 33Status Active
CGTLimited DatastaleAdaptimmunePreclinical

Genetically engineered T Cell Receptors (Genetically engineered T Cell Receptors)

Solid and Hematological Malignancies · Solid and Hematological Malignancies

#SolidandHematologicalMalignancie#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 30Status Discontinued
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
CGTStandard DatabasestaleTakedaPhase 2

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Hematologic Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 10Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
AntibodyLimited DatastaleAntengene Therapeutics LimitedPhase 1

nivolumab (Opdivo, ATG-017+Nivolumab)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Discontinued
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 2

Anti-CD7 CAR-T (Anti-CD7 CAR-T)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

C9/CD5CAR/IL-15 NK cells (C9/CD5CAR/IL-15 NK cells)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 1

CAR-37 T cells (CAR-37 T cells)

Hematologic Malignancy; Leukemia · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD123-CD33 cCAR T cells (CD123-CD33 cCAR T cells)

Hematologic Malignancy; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChang YingjunPhase 2

CD19-BCMA dual nanobody based CAR-T Cells (CD19-BCMA dual nanobody based CAR-T Cells)

Transplantation Candidates With Hematological Diseases · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing JD Biotech Co. LTD.Phase 1

CD19-CAR-NK (CD19-CAR-NK)

Adult Relapsed/Refractory B-cell Hematologic Malignancies · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleHe HuangPhase 1

CD20/CD22 dual Targeted CAR T-cells (CD20/CD22 dual Targeted CAR T-cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →